LAG3 Expression in Triple Negative Breast Cancer
Recruiting
N/A
Interventional Study
Triple Negative Breast Cancer
Immune Checkpoint Inhibitor
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Sex
- Female
- Study type
- Interventional
- Purpose
- Screening
- Participants needed
- 128 (estimated)
- Sponsor
- Samsung Medical Center · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Planned neoadjuvant chemotherapy
* Triple negative breast cancer
Exclusion Criteria:
* HER2-positive breast cancer
* Hormone receptor positive breast cancer
Contacts